All In Biotech

NDA 018679 · Dr Reddys Labs SA

Trimethoprim

Trimethoprim · Oral · Dihydrofolate Reductase Inhibitor Antibacterial

Last checked: Nov 19, 2026Latest source record: Aug 11, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

Jul 30, 1982

Approved uses

1

Original approval plus efficacy supplements

Registered trials

259

71 Phase 3, 36 recruiting

FAERS reports

11,863

10,877 serious, 1,558 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 26, 2024.

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets, USP and other antibacterial drugs, trimethoprim tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Proteus mirabilis , Klebsiella pneumoniae , Enterobacter species, and coagulase-negative Staphylococcus species, including S. saprophyticus . Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests.

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 30, 1982 Original approval
1 products under this application
  • TRIMETHOPRIM · TRIMETHOPRIM 100MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Trimethoprim" as an intervention, any sponsor and status, largest first.

All 259 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea977
  • off label use959
  • headache910
  • diarrhoea876
  • malaise870
  • drug ineffective801
  • dyspnoea763
  • pyrexia749
  • vomiting746
  • fatigue683
  • rash633
  • dizziness632

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200499
2005126
2006139
2007172
2008161
2009209
2010238
2011344
2012430
2013443
2014603
2015677
2016722
2017541
2018848
2019931
2020877
2021852
2022842
2023782
2024756
2025625
2026445

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Trimethoprim (Trimethoprim)

2024 spending

$10.2M

Beneficiaries

54,995

186,969 claims

Per beneficiary

$185

$1.12 per unit

View as table
YearSpending
2020$4,041,562
2021$4,166,076
2022$9,056,631
2023$9,528,512
2024$10,161,642

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,415 on PubMed

Sponsor: Dr Reddys Labs SA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.